Literature DB >> 7539040

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

B Fisk1, T L Blevins, J T Wharton, C G Ioannides.   

Abstract

Synthetic peptide analogues of sequences in the HER-2 protooncogene (HER-2) were selected based on the presence of HLA-A2.1 anchor motifs to identify the epitopes on HER-2 recognized by ovarian tumor-reactive CTL. 19 synthetic peptides were evaluated for recognition by four HLA-A2 ovarian-specific cytotoxic T lymphocyte (CTL) lines obtained from leukocytes associated with ovarian tumors. The nonapeptide E75 (HER-2, 369-377:KIFGSLAFL) was efficient in sensitizing T2 cells for lysis by all four CTL lines. This peptide was specifically recognized by cloned CD8+ CTL isolated from one of the ovarian-specific CTL lines. E75-pulsed T2 cells inhibited lysis by the same CTL clone of both an HLA-A2+ HER-2high ovarian tumor and a HER-2high cloned ovarian tumor line transfected with HLA-A2, suggesting that this or a structurally similar epitope may be specifically recognized by these CTL on ovarian tumors. Several other HER-2 peptides were recognized preferentially by one or two CTL lines, suggesting that both common and private HER-2 epitopes may be immunogenic in patients with ovarian tumors. Since HER-2 is a self-antigen, these peptides may be useful for understanding mechanisms of tumor recognition by T cells, immunological tolerance to tumor, and structural characterization of tumor antigens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539040      PMCID: PMC2192068          DOI: 10.1084/jem.181.6.2109

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.

Authors:  E M Letessier; D S Heo; T Okarma; J T Johnson; R B Herberman; T L Whiteside
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

2.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

3.  Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.

Authors:  F Rilke; M I Colnaghi; N Cascinelli; S Andreola; M T Baldini; R Bufalino; G Della Porta; S Ménard; M A Pierotti; A Testori
Journal:  Int J Cancer       Date:  1991-08-19       Impact factor: 7.396

4.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

6.  Folate-binding protein is a marker for ovarian cancer.

Authors:  I G Campbell; T A Jones; W D Foulkes; J Trowsdale
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

7.  Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells.

Authors:  C G Ioannides; R S Freedman; C D Platsoucas; S Rashed; Y P Kim
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

8.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

Authors:  S Gendler; J Taylor-Papadimitriou; T Duhig; J Rothbard; J Burchell
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

9.  Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

Authors:  B Fisk; C G Ioannides; S Aggarwal; J T Wharton; C A O'Brian; N Restifo; B S Glisson
Journal:  Lymphokine Cytokine Res       Date:  1994-04

10.  Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide.

Authors:  K T Hogan; N Shimojo; S F Walk; V H Engelhard; W L Maloy; J E Coligan; W E Biddison
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  101 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

3.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

Review 4.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

Review 5.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 6.  Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Authors:  Ishwaria M Subbiah; Ana Maria Gonzalez-Angulo
Journal:  Curr Treat Options Oncol       Date:  2014-03

7.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 8.  The cancer antigenome.

Authors:  Bianca Heemskerk; Pia Kvistborg; Ton N M Schumacher
Journal:  EMBO J       Date:  2012-12-21       Impact factor: 11.598

Review 9.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

Review 10.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.